

Remarks

Applicants have canceled claims 1-36 and have added new claims 37-45. Support for the added claims is found in the specification and claims as filed.

Support for claims relating to a nucleic acid delivery complex are found, for example, at page 11 and page 20, line 33 – page 21, line 2 (describing an oligonucleotide delivery complex, ionic and covalent linkage or association or encapsulation of an oligonucleotide with a molecule e.g., cationic lipid, sterol, liposome, virosome). Support is also found on page 22, lines 17-25 which describe pharmaceutically acceptable carriers.

Support for oligonucleotide comprising the sequence 5'-TGACGTT-3' and 5'TGACGTC3' is found, for example, at page 10, line 18.

Support for oligonucleotide comprising the sequence 5'-AACGTT-3'and 5'-TCAACGTT-3' is found, for example, at page 13, lines 20-21.

Support for the oligonucleotide having a length of 8-40 nucleotides is found in the specification page 7, lines 21-22 and page 10 lines 12-13.

Support for the oligonucleotide having a phosphate backbone modification such as a phosphorothioate is found page 9, lines 27-36.

CONCLUSION

If there is a fee occasioned by this response that is not covered by an enclosed check, please charge any deficiency to Deposit Account No. 23/2825.

Respectfully submitted,



Helen Lockhart, Reg. No. 39,248
WOLF, GREENFIELD & SACKS, P.C.
Federal Reserve Plaza
600 Atlantic Avenue
Boston, Massachusetts 02210
Tel.: (617) 720-3500

Docket No.: C1039.70083US07

Date: February 26, 2004